- European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
More ▼
Key statistics
On Friday, Organon & Co (OGN:NYQ) closed at 20.70, -14.04% below its 52-week high of 24.08, set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.76 |
---|---|
High | 21.03 |
Low | 20.52 |
Bid | 20.45 |
Offer | 20.79 |
Previous close | 20.59 |
Average volume | 1.49m |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.08 |
Market cap | 5.32bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 1.12 USD |
---|---|
Annual div yield (ADY) | 5.41% |
Div ex-date | May 10 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 15 minutes, as of Jun 28 2024 21:10 BST.
More ▼